NextFin News -- Chinese researchers have unveiled what they describe as the world’s first platform capable of conducting virtual drug screening across a molecular library of nearly 100 billion compounds within seconds.
The new platform, called GalaxyVS, was jointly developed by Tsinghua University and the National Supercomputing Center in Tianjin.
Designed for ultra-large-scale virtual drug screening, GalaxyVS can analyze millions of target protein pockets against a compound library containing nearly 100 billion synthesizable and commercially available molecules — currently considered the world’s largest accessible chemical resource database.
Powered by China’s next-generation Tianhe supercomputing system, the platform marks the first time globally that second-level virtual screening has been achieved on a molecular library of this scale, the report said.
Researchers said the technology could significantly accelerate drug discovery and expand possibilities for pharmaceutical development across a wide range of species.
Explore more exclusive insights at nextfin.ai.
Insights
What are the technical principles behind virtual drug screening?
What is the origin of the GalaxyVS platform?
What is the current market situation for virtual drug screening technologies?
How has user feedback been regarding the GalaxyVS platform?
What industry trends are influencing the development of supercomputing in drug discovery?
What are the latest updates about the GalaxyVS platform's capabilities?
Are there any recent policy changes affecting drug discovery in China?
What are the future outlooks for supercomputing in pharmaceutical development?
What long-term impacts could GalaxyVS have on the drug discovery process?
What challenges does the GalaxyVS platform face in implementation?
What are some controversies surrounding the use of supercomputers in drug discovery?
How does GalaxyVS compare to other virtual drug screening platforms?
What historical cases have influenced the development of drug screening technologies?
What similar concepts exist in drug discovery that may impact GalaxyVS's adoption?
What technologies will be crucial for future growth in the global drug screening market?
In what ways could GalaxyVS expand possibilities for pharmaceutical development?
